The DOI matches its Crossref record; 31 of the 31 references it cites were found in a registry or an index.
Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions
Open accessAbstract
BACKGROUND: Preclinical evaluation of tuberculosis drugs is generally limited to mice. However, necrosis and hypoxia, key features of human tuberculosis lesions, are lacking in conventional mouse strains. METHODS: We used C3HeB/FeJ mice, which develop necrotic lesions in response to Mycobacterium tuberculosis infection. Positron emission tomography in live infected animals, postmortem pimonidazole immunohistochemistry, and bacterial gene expression analyses were used to assess whether tuberculosis lesions in C3HeB/FeJ are hypoxic. Efficacy of combination drug treatment, including PA-824, active against M. tuberculosis under hypoxic conditions, was also evaluated. RESULTS: Tuberculosis lesions in C3HeB/FeJ (but not BALB/c) were found to be hypoxic and associated with up-regulation of known hypoxia-associated bacterial genes (P < .001). Contrary to sustained activity reported elsewhere in BALB/c mice, moxifloxacin and pyrazinamide (MZ) combination was not bactericidal beyond 3 weeks in C3HeB/FeJ. Although PA-824 added significant activity, the novel combination of PA-824 and MZ was less effective than the standard first-line regimen in C3HeB/FeJ. CONCLUSIONS: We demonstrate that tuberculosis lesions in C3HeB/FeJ are hypoxic. Activities of some key tuberculosis drug regimens in development are represented differently in C3HeB/FeJ versus BALB/c mice. Because C3HeB/FeJ display key features of human tuberculosis, this strain warrants evaluation as a more pathologically relevant model for preclinical studies.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
A small-molecule nitroimidazopyran drug candidate for the treatment of tuberculosis
Stover, C. K., Warrener, P., VanDevanter, D. R., Sherman, D. R., Arain, T. M., Langhorne, M. H., Anderson, S. W., Towell, J. A., Yuan, Y., McMurray, D. N., et al. (2000) · Nature · doi:10.1038/35016103 · Cited by 1,034
Molecular imaging in drug discovery and development
Rudin, M., & Weissleder, R. (2003) · Nature Reviews Drug Discovery · doi:10.1038/nrd1007 · Cited by 815
Regulation of the Mycobacterium tuberculosis hypoxic response gene encoding α-crystallin
Sherman, D. R., Voskuil, M., Schnappinger, D., Liao, R., Harrell, M. I., & Schoolnik, G. K. (2001) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.121172498 · Cited by 729
Tuberculous Granulomas Are Hypoxic in Guinea Pigs, Rabbits, and Nonhuman Primates
Via, L. E., Lin, P. L., Ray, S. M., Carrillo, J., Allen, S. S., Eum, S. Y., Taylor, K., Klein, E., Manjunatha, U., Gonzales, J., et al. (2008) · Infection and Immunity · doi:10.1128/iai.01515-07 · Cited by 664
PA-824 Kills Nonreplicating Mycobacterium tuberculosis by Intracellular NO Release
Singh, R., Manjunatha, U., Boshoff, H. I. M., Ha, Y. H., Niyomrattanakit, P., Ledwidge, R., Dowd, C. S., Lee, I. Y., Kim, P., Zhang, L., et al. (2008) · Science · doi:10.1126/science.1164571 · Cited by 628
The Enduring Hypoxic Response of Mycobacterium tuberculosis
Rustad, T. R., Harrell, M. I., Liao, R., & Sherman, D. R. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001502 · Cited by 491
Copper-62-ATSM: a new hypoxia imaging agent with high membrane permeability and low redox potential.
Fujibayashi, Y., Taniuchi, H., Yonekura, Y., Ohtani, H., Konishi, J., & Yokoyama, A. (1997) · PubMed · Cited by 481
Ipr1 gene mediates innate immunity to tuberculosis
Pan, H., Yan, B.-S., Rojas, M., Shebzukhov, Y. V., Zhou, H., Kobzik, L., Higgins, D. E., Daly, M. J., Bloom, B. R., & Kramnik, I. (2005) · Nature · doi:10.1038/nature03419 · Cited by 480
Self-citationVoskuil, M. I., Visconti, K. C., & Schoolnik, G. K. (2004) · Tuberculosis · doi:10.1016/j.tube.2004.02.003 · Cited by 448
Molecular Genetics of Mycobacteria
(2014) · ASM Press eBooks · doi:10.1128/9781555818845 · Cited by 429
Cited by
Mycobacterium tuberculosis: success through dormancy
Gengenbacher, M., & Kaufmann, S. H. E. (2012) · FEMS Microbiology Reviews · doi:10.1111/j.1574-6976.2012.00331.x · Cited by 696
Hit and lead criteria in drug discovery for infectious diseases of the developing world
Katsuno, K., Burrows, J. N., Duncan, K., van Huijsduijnen, R. H., Kaneko, T., Kita, K., Mowbray, C. E., Schmatz, D., Warner, P., & Slingsby, B. T. (2015) · Nature Reviews Drug Discovery · doi:10.1038/nrd4683 · Cited by 607
Heterogeneity in tuberculosis pathology, microenvironments and therapeutic responses
Lenaerts, A., Barry, C. E., & Dartois, V. (2015) · Immunological Reviews · doi:10.1111/imr.12252 · Cited by 362
Silva Miranda, M., Breiman, A., Allain, S., Deknuydt, F., & Altare, F. (2012) · Clinical and Developmental Immunology · doi:10.1155/2012/139127 · Cited by 318
Targeting Persisters for Tuberculosis Control
Zhang, Y., Yew, W. W., & Barer, M. R. (2012) · Antimicrobial Agents and Chemotherapy · doi:10.1128/aac.06288-11 · Cited by 271
Metadata
- Authors
- Harper, J., Skerry, C., Davis, S. L., Tasneen, R., Weir, M., Kramnik, I., Bishai, W. R., Pomper, M. G., Nuermberger, E. L., & Jain, S. K.
- Venue
- The Journal of Infectious Diseases
- Publisher
- Oxford University Press (OUP)
- Published
- 2011-12-23
- Volume
- 205
- Issue
- 4
- Pages
- 595-602
- ISSN
- 0022-1899 (ISSN-L)
- 1537-6613
- OpenAlex
- W2161458072
- Cited by
- 256
- References
- 31
- FWCI
- 9.61
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions. https://app.cochat.ai/papers/10.1093/infdis/jir786
- The paper
- Harper, J., Skerry, C., Davis, S. L., Tasneen, R., Weir, M., Kramnik, I., Bishai, W. R., Pomper, M. G., Nuermberger, E. L., & Jain, S. K. (2012). Mouse Model of Necrotic Tuberculosis Granulomas Develops Hypoxic Lesions. The Journal of Infectious Diseases. https://doi.org/10.1093/infdis/jir786
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.